Alembic Pharmaceuticals Limited (IN:APLLTD)
:APLLTD
Want to see IN:APLLTD full AI Analyst Report?
APLLTD Stock Chart & Stats
₹930.30
-₹4.90(-0.46%)
At close: 4:00 PM EST
₹930.30
-₹4.90(-0.46%)
Day’s Range― - ―
52-Week Range₹635.30 - ₹1,107.80
Previous CloseN/A
Volume60.71K
Average Volume (3M)9.71K
Market Cap
₹147.95B
Enterprise Value₹160.16B
Total Cash (Recent Filing)₹1.55B
Total Debt (Recent Filing)₹14.89B
Price to Earnings (P/E)19.3
Beta1.01
Next Earnings
Jul 31, 2026EPS Estimate
5.4Next Dividend Ex-DateN/A
Dividend Yield1.28%
Share Statistics
EPS (TTM)32.24
Shares Outstanding196,563,130
10 Day Avg. Volume3,953
30 Day Avg. Volume9,706
Financial Highlights & Ratios
PEG Ratio1.23
Price to Book (P/B)2.30
Price to Sales (P/S)1.77
P/FCF Ratio50.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.02
Revenue Forecast (FY)₹82.21B
Bulls Say, Bears Say
Bulls Say
Conservative LeverageA low debt-to-equity (~0.25) and expanding shareholders' equity give durable financial flexibility. This conservatism helps fund R&D, capex, or selective M&A without stressing liquidity, reduces refinancing risk in downturns, and supports continuity of operations across cycles.
Diversified Revenue BaseMulti-geography and multi-product revenue (India branded generics, APIs, US generics) plus steady multi-year growth reduce single-market dependence. This diversification supports more durable cash flows and scale advantages in manufacturing and distribution across market cycles.
Solid Returns & Improving MarginsAn ROE around 12% and mid-single-digit net margins with stable operating margins indicate efficient capital use and core profitability. These metrics support reinvestment capacity and sustained cash generation potential if operational discipline is maintained.
Bears Say
Cash-Flow VolatilityLarge year-to-year swings in operating and free cash flow signal execution and working-capital variability. Persistent volatility undermines forecastability for capex, dividends and debt servicing, forcing higher cash buffers or occasional external financing during weak periods.
Margin Compression RiskMargins have deteriorated from earlier peaks, indicating pressure from pricing, mix shifts, or cost changes. Sustained margin compression reduces earnings power and makes profitability more sensitive to pricing pressure in generic markets and input-cost inflation.
Execution & Regulatory Dependence (US)Material exposure to the US generics market ties results to approval timing, launch execution and intense price competition. Delays, failed approvals, or aggressive competitor pricing can materially depress revenues and cash conversion over multi-quarter horizons.
Alembic Pharmaceuticals Limited News
APLLTD FAQ
What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?
Alembic Pharmaceuticals Limited lowest stock price was ₹635.30 and its highest was ₹1107.80 in the past 12 months.
What is Alembic Pharmaceuticals Limited’s market cap?
Alembic Pharmaceuticals Limited’s market cap is ₹147.95B.
When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?
Alembic Pharmaceuticals Limited’s upcoming earnings report date is Jul 31, 2026 which is in 71 days.
How were Alembic Pharmaceuticals Limited’s earnings last quarter?
Alembic Pharmaceuticals Limited released its earnings results on May 15, 2026. The company reported ₹10.2 earnings per share for the quarter, beating the consensus estimate of ₹8.655 by ₹1.545.
Is Alembic Pharmaceuticals Limited overvalued?
According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued.
Does Alembic Pharmaceuticals Limited pay dividends?
Alembic Pharmaceuticals Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 1.28%. See more information on Alembic Pharmaceuticals Limited dividends here
What is Alembic Pharmaceuticals Limited’s EPS estimate?
Alembic Pharmaceuticals Limited’s EPS estimate is 5.4.
How many shares outstanding does Alembic Pharmaceuticals Limited have?
Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.
What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?
Alembic Pharmaceuticals Limited reported an EPS of ₹10.2 in its last earnings report, beating expectations of ₹8.655. Following the earnings report the stock price went down -0.223%.
Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:APLLTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Technical Analysis
GlaxoSmithKline Pharmaceuticals Limited
―
JB Chemicals & Pharmaceuticals Ltd.
―
Jubilant Pharmova Limited
―
Marksans Pharma Limited
―
NATCO Pharma Limited
―